| | Home | Back To Index | |
|
|
||||||||||||||
|
Today's pharmaceutical industry is shifting toward biopharmaceuticals at a drastic speed. In 2009, sales of biopharmaceutical drugs accounted for 13% of the total sales of pharmaceuticals. And today, biopharmaceuticals account for 25% of all pharmaceuticals in the development pipeline. We expect that biopharmaceuticals will maintain double digit growth in the years to come, and form a rapidly growing market. Eying this dramatically expanding market, companies are expanding biopharmaceutical discovery and development, and becoming active in M&A activities including involvement in bio-ventures. As a result, competition is becoming increasingly fierce. In this study, we describe and report on the current state and future trends of biopharmaceutical drugs in the global market, including:
Disease Categories:
Major Companies:
1. Market Overview 1.1 Worldwide Biopharmaceutical Drug Market Table 1.1: Worldwide Biopharmaceutical Drug vs. Medical Drug Table 1.2: Worldwide Biopharmaceutical Drug vs. Medical Drug by Region 1.2 Noteworthy Biopharmaceutical Drug 1.3 Worldwide Biopharmaceutical Drug R&D Table 1.3: Biopharmaceutical Drug R&D Expenditure by Region 1.4 Noteworthy Biopharmaceutical Drug Company for R&D expenditure Table 1.4 Top 10 Company R&D Expenditure for Biopharmaceutical Drug 2. Worldwide Biopharmaceutical Drug Market Trends, 2009 - 2013 2.1 Worldwide Total Biopharmaceutical Drug Market by Company, 2009 Table 2.1: Global Sales of Biopharmaceutical Drugs by 25 Companies, 2009 Figure 2.1: Worldwide Market Share of top 15 Manufacturers of Biopharmaceutical Drugs, 2009 2.2 Worldwide Total Biopharmaceutical Drug Market by Disease Category, 2009 - 2013 Table 2.2: Worldwide Sales of All Biopharmaceuticals by 20 Categories, 2009 - 2013 2.3 Worldwide Total Biopharmaceutical Drug Market by Branded Product, 2009 - 2013 Table 2.3: Worldwide Sales of All Biopharmaceuticals by 109 Branded Products, 2009 - 2013 2.4 Worldwide Total Biopharmaceutical Drug Market by Region, 2009 - 2013 Table 2.5: Worldwide Sales of All Biopharmaceuticals by World Region, 2009 - 2013 3. US Biopharmaceutical Drug Market, 2009 - 2013 3.1 Overview 3.1.1 Industry & Market Current Trends 3.1.2 Industry Spending for Biopharmaceutical R&D 3.1.3 US Prescription Volume for Biopharmaceuticals 3.2 US Sales of Biopharmaceutical Drugs 3.2.1 US Sales of Biopharmaceutical Drug by Disease Category Table 3.1: US Sales of All Biopharmaceuticals by 20 Categories, 2009 - 2013 3.2.2 US Sales of Biopharmaceutical Drugs by Company Table 3.2: US Sales of Biopharmaceutical Drugs by 23 Companies, 2009 Figure 3.1: US Market Share of 15 Manufacturers of Biopharmaceutical Drugs, 2009 3.2.3 US Sales of Biopharmaceutical Drugs by 20 Disease Categories Common Research Items: ·US Sales of Biopharmaceutical Drugs, 2009 ·US Market Share of Biopharmaceutical Players, 2009 ·US Sales of Biopharmaceutical Drugs, 2009-2013 ·US Sales Growth of Biopharmaceutical Companies, 2009-2013 3.2.3.1 Alzheimer's Disease 3.2.3.2 Anemia 3.2.3.3 Arthritis 3.2.3.4 Asthma 3.2.3.5 Cancer 3.2.3.6 Cryopyrin-Associated Periodic Syndrome (CAPS) 3.2.3.7 Diabetes 3.2.3.8 Fabry Disease 3.2.3.9 Gaucher's Disease 3.2.3.10 Growth Hormone Deficiency 3.2.3.11 Hepatitis C 3.2.3.12 HIV 3.2.3.13 Lupus 3.2.3.14 Multiple Sclerosis 3.2.3.15 Neutropenia 3.2.3.16 Osteoporosis 3.2.3.17 Parkinson's Disease 3.2.3.18 Transplant Rejection 3.2.3.19 Ulcerative Colitis 3.2.3.20 Vaccines 3.2.3.21 Other Conditions 3.3 Issues and Sales Drivers 4. Worldwide Innovative Biopharmaceutical Drug Development by Disease Categories 4.1 New Drug Pipelines and Players for Future Growth by 20 disease Categories Table 4.1: At Glance 4.1.1 Alzheimer's Disease - 4.1.21 Other Conditions 4.2 New Players to Enter the Market by 20 Disease Categories 4.2.1 Alzheimer's Disease - 4.2.21 Other Conditions 4.3 Beyond the Pipeline: Hot Categories and Players' Product Development Strategy 5. Worldwide Biopharmaceutical Strategy by Major Company 5.1 Major Alliances, M&A and IP Table 5.1: Major Biotech Alliances, 2009 5.2 Worldwide Biopharmaceutical Drug Strategies by Company 5.2.1 Abbott Laboratories 5.2.2 Amgen 5.2.3 Bayer 5.2.4 Biogen Idec 5.2.5 Bristol-Myers Squibb 5.2.6 Chugai Pharmaceutical Co., Ltd. 5.2.7 Daiichi Sankyo Co. Ltd. 5.2.8 Elan 5.2.9 Eli Lilly 5.2.10 Genetech 5.2.11 Genzyme 5.2.12 GlaxoSmithKline 5.2.13 Human Genome Sciences 5.2.14 Johnson & Johnson 5.2.15 Kyowa Hakko Kirin Co., Ltd. 5.2.16 Merck 5.2.17 Merck Serono 5.2.18 Novartis 5.2.19 Novo Nordisk 5.2.20 Pfizer 5.2.21 Regeneron 5.2.22 Roche 5.2.23 Sanofi-Aventis 5.2.24 Shire 5.2.25 Swedish Orphan Biovitrum 5.2.26 Takeda Pharmaceutical Co., Ltd. 5.2.27 UCB 5. 3 Worldwide Biopharmaceutical Drug R&D by Major Company 5.3.1 Abbott Laboratories - 5.3.34 UCB Pharma (Total 34 Companies) 5.4 Patents, Business Development & Challenges for Worldwide Biopharmaceutical Drug Major Company 5.4.1 Abbott Laboratories - 5.4.28 UCB (Total 28 Companies) 6. Important Findings and Suggestions/Recommendations for Business Opportunities 7. Appendix 7.1 Selected Companies Mentioned in this Report Table 7.1: Major Biopharmaceutical Companies FOR ORDER OR INQUIRY, PLEASE CLICK "ORDER / INQUIRY FORM" |